Well-Balanced: Akero Therapeutics (AKRO) Reports Encouraging NASH Trial Data

Akero Therapeutics Inc.'s (AKRO) phase IIa study of its investigational drug AKR-001 in patients with biopsy-confirmed nonalcoholic steatohepatitis, or NASH, has met the primary endpoint.

from RTT - Before the Bell https://ift.tt/2UQ9IYb
via IFTTT